Accession Number : ADA580049


Title :   Development of a Combination Therapy for Prostate Cancer by Targeting Stat3 and HIF-1alpha


Descriptive Note : Final rept. 1 Jul 2010-30 Jun 2013


Corporate Author : BAYLOR COLL OF MEDICINE HOUSTON TX


Personal Author(s) : Jing, Naijie


Full Text : https://apps.dtic.mil/dtic/tr/fulltext/u2/a580049.pdf


Report Date : Jul 2013


Pagination or Media Count : 19


Abstract : It is becoming increasingly evident that improving the cure rate of many cancers will require treatment regimens hit more than one validated tumor targets. Developing an anti-cancer agent that targets two oncorproteins simultaneously is a promising strategy for accomplishing this goal. It would be expected to promote drug efficacy, reduce therapy-resistant without introducting additional toxic side effects. Recently, we have identified TEL03 from Chinese medicinal herb significantly inhibits activations of HIF-1alpha/2alpha and phosphorylated Stat3 (p-Stat3), and blocks the expression of their down-regulated oncogenes (e.g. Bcl2, VEGF, Glut1, and others) in cancer cells. TEL03 also dramatically suppressed the growth of prostate, breast and pancreatic tumors in xenograft models. Our previous studies provided evidence that targeting both HIF-1alpha and Stat3 together could improve tumor response to either agent alone, and reduce drug resistance and treatment failure.


Descriptors :   *CHEMOTHERAPEUTIC AGENTS , *GROWTH(PHYSIOLOGY) , *PROSTATE CANCER , CANCER , CURING , DRUGS , MAMMARY GLANDS , NEOPLASMS , PANCREAS , RESPONSE , STRATEGY , SUPPRESSION , TOXICITY , VALIDATION


Subject Categories : Medicine and Medical Research
      Pharmacology


Distribution Statement : APPROVED FOR PUBLIC RELEASE